Cardiol Therapeutics (CRDL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2025 | 12-2024 | 09-2024 | 06-2024 | 03-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -5,772 | -26,767 | -20,890 | -11,524 | -6,805 |
| Depreciation Amortization | 17 | 272 | 238 | 90 | 46 |
| Accounts receivable | 17 | 31 | 63 | 36 | -8 |
| Other Working Capital | -106 | -680 | -1,409 | 549 | -23 |
| Other Operating Activity | 861 | 8,854 | 7,728 | 2,300 | 1,659 |
| Operating Cash Flow | $-4,982 | $-18,289 | $-14,270 | $-8,548 | $-5,132 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -8 | -16 | -11 | -5 | -3 |
| Investing Cash Flow | $-8 | $-16 | $-11 | $-5 | $-3 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | 15,715 | 130 | 130 | 67 |
| Other Financing Activity | -10 | -1,965 | -20 | -17 | -10 |
| Financing Cash Flow | $-10 | $13,750 | $110 | $113 | $57 |
| Exchange Rate Effect | -75 | 1,379 | 210 | 468 | 364 |
| Beginning Cash Position | 21,296 | 25,493 | 25,605 | 25,525 | 25,895 |
| End Cash Position | 16,221 | 22,317 | 11,644 | 17,552 | 21,181 |
| Net Cash Flow | $-5,075 | $-3,176 | $-13,961 | $-7,972 | $-4,714 |
| Free Cash Flow | |||||
| Operating Cash Flow | -4,982 | -18,289 | -14,270 | -8,548 | -5,132 |
| Capital Expenditure | -8 | -16 | -11 | -5 | -3 |
| Free Cash Flow | -4,990 | -18,305 | -14,281 | -8,553 | -5,135 |